Compare TK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | INBX |
|---|---|---|
| Founded | 1973 | 2010 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 937.1M | 999.7M |
| IPO Year | 1995 | 2024 |
| Metric | TK | INBX |
|---|---|---|
| Price | $12.90 | $63.92 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 501.7K | 169.7K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 15.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $5.83 | $10.81 |
| 52 Week High | $13.76 | $94.57 |
| Indicator | TK | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 64.02 | 43.47 |
| Support Level | $8.99 | $57.30 |
| Resistance Level | $13.76 | $85.97 |
| Average True Range (ATR) | 0.47 | 4.57 |
| MACD | 0.08 | 0.28 |
| Stochastic Oscillator | 98.31 | 41.88 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.